Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aptinyx Inc. APTX
$0.09
+$0 (1.54%)
На 18:01, 12 мая 2023
+1 011.11%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
6365275.00000000
-
week52high
0.75
-
week52low
0.06
-
Revenue
0
-
P/E TTM
0
-
Beta
1.33433700
-
EPS
-0.96000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 26 авг 2022 г. |
| Truist Securities | Hold | Buy | 16 авг 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 16 авг 2022 г. |
| BMO Capital | Outperform | Outperform | 15 авг 2022 г. |
| Piper Sandler | Neutral | Overweight | 12 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KIDD ANDREW | A | 700000 | 700000 | 03 янв 2023 г. |
| RIEDEL NORBERT G | A | 420000 | 420000 | 03 янв 2023 г. |
| KHANNA ASHISH | A | 375000 | 375000 | 03 янв 2023 г. |
| Koppel Adam | A | 40000 | 40000 | 26 мая 2022 г. |
| ENRIGHT PATRICK G | A | 40000 | 40000 | 26 мая 2022 г. |
| Sherman Rachel E. | A | 40000 | 40000 | 26 мая 2022 г. |
| HOMBACH ROBERT J. | A | 40000 | 40000 | 26 мая 2022 г. |
| Gosebruch Henry O | A | 40000 | 40000 | 26 мая 2022 г. |
| Gould Terry P | A | 40000 | 40000 | 26 мая 2022 г. |
| Miller Joan W. | A | 40000 | 40000 | 26 мая 2022 г. |
Новостная лента
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research
30 мар 2023 г. в 11:23
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Zacks Investment Research
21 мар 2023 г. в 13:00
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Why Is Aptinyx (APTX) Stock Down 64% Today?
InvestorPlace
28 февр 2023 г. в 08:36
Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary endpoint.
Aptinyx to Present at the SVB Securities Global Biopharma Conference
Business Wire
31 янв 2023 г. в 07:47
EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
08 ноя 2022 г. в 21:46
Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and CMC Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call.